Specialty Pharmaceuticals

Novel Formulations Solving Unmet Clinical Needs


Franck Rousseau, M.D.

Chief Executive Officer

Franck Rousseau became CEO of Banner Life Sciences in 2018 after serving as Chief Operating Officer since 2016. Before joining Banner Life Sciences, Dr. Rousseau had been Chief Medical Officer of two North Carolina-based companies, Tranzyme and Ocera.

After training as a physician, Franck rose through the clinical development ranks at GlaxoWellcome and then joined a startup biotech, Triangle Pharmaceuticals, in 1997 where he served as Chief Medical Officer until the company’s acquisition by Gilead in 2003. Franck then ran Gilead’s site in Durham, NC from 2003-2010.

Dr. Rousseau holds a B.A. from the University of Paris 6, and his M.D. from the University of Paris, College of Medicine. Dr. Rousseau has a Degree of Epidemiology and Nosocomial Infections from the University of Paris 7, and a Degree in Biostatistics from University Paris 2, Paris, France.


Tom Lategan, Ph.D.

Vice President, Regulatory Affairs

Tom Lategan joined Banner Life Sciences in 2015 as Vice President of Regulatory Affairs. Prior to that, Dr. Lategan served as Vice President of Regulatory Affairs and Head of Clinical Operations at NeurAxon, Inc., a pharmaceutical start-up focused on nitric oxide synthase inhibition.

Between 2000 and 2007, Dr. Lategan served on the senior leadership team as Vice President of Regulatory Affairs at Actelion. There, he oversaw all US regulatory activities, helping lead the company through approval and launch of Tracleer® (bosentan) and Zavesca® (miglustat).

Dr. Lategan joined Actelion after leaving The Medicines Company,  Inc., where he was Vice President of Product Value. During his tenure at The Medicines Company, he oversaw the submission of the Angiomax® (bivalirudin) NDA and conduct of preclinical and clinical studies.

Dr. Lategan also spent nine years at Hoffmann-La Roche, both in Switzerland and the US, holding positions of increasing responsibilities in regulatory and medical affairs.

Dr. Lategan has more than 20 years of experience spanning large-cap, and start-up companies in the pharmaceutical industry. He holds an B.Sc. in pharmacology from Aberdeen University in Scotland, and a D.Phil. from Oxford University.


Nikki Sprague

Vice President of Projects and Operations

Nikki Sprague has over a decade of project and program management experience in drug development. Since joining Banner in 2008, she has held positions of increasing responsibility and portfolio complexity. She has extensive experience leading R&D project teams through the development, submission, approval, launch, and life cycle management of numerous ANDA and NDA505(b)(2) products. As Banner Life Sciences restructured into specialty pharma, Nikki became responsible for all aspects of project management for the development portfolio.

Nikki holds a B.Sc. in Chemistry from the University of Virginia, and a Master’s degree in Biochemistry from Florida State University. She has maintained PMP certification since 2009.